Latest news with #2025Bloom
Business Wire
29-04-2025
- Business
- Business Wire
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference taking place in Toronto on May 5 and 6. Satellos Co-founder and CEO Frank Gleeson will provide a presentation on May 5 and along with members of the management team, will participate in one-on-one meetings during the conference. 2025 Bloom Burton & Co. Healthcare Investor Conference Format: Presentation and webcast Presenter: Frank Gleeson, President and CEO Date: Monday, May 5 Time: 11:30 a.m. ET Location: Metro Toronto Convention Centre The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentation. About Satellos Bioscience Inc. Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration in degenerative or injury conditions by correcting muscle stem cell polarity. Satellos has generated a body of preclinical evidence with SAT-3247 to support its discovery that correcting muscle stem cell polarity has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has degenerated or been damaged. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Additionally, Satellos is leveraging its research and proprietary discovery platform MyoReGenX™, to identify additional degenerative muscle diseases or injury conditions where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit
Yahoo
29-01-2025
- Business
- Yahoo
Bloom Burton & Co. Announces the 2025 Bloom Burton Award
Now Accepting Nomination Submissions for the Prestigious Annual Award Toronto, Ontario--(Newsfile Corp. - January 29, 2025) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce the launch of the 2025 Bloom Burton Award and to open nomination submissions from the public at large on or before March 31, 2025. The finalists for the 2025 Bloom Burton Award will be announced at the 2025 Bloom Burton & Co. Healthcare Investor Conference, taking place at the Metro Toronto Convention Centre from May 5-6, 2025. Bloom Burton & Co. Announces the 2025 Bloom Burton AwardTo view an enhanced version of this graphic, please visit: Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada's innovative healthcare industry in the previous year. Nominees will be accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health services or healthcare IT sectors, and equal consideration will be given to contributions across any stage of development – from discovery to commercial end-markets. The winner will be selected by our distinguished panel of judges, comprised of respected international leaders in healthcare investment, entrepreneurship, and journalism: Michael Altman, Managing Director, Perceptive Advisors Christopher Arendt, Chief Scientific Officer, Head of Research, Takeda Karen Bernstein, Co-Founder and Chairman, BioCentury Joan Eliasek, President, McKesson Canada Carl Gordon, Managing Partner, OrbiMed Dennis Purcell, Founder and Senior Advisor, Aisling Capital Melinda Richter, Global Head, Johnson & Johnson Innovation - JLABS Camille Samuels, Director, Venrock Boards Brian Bloom, Chairman & Chief Executive Officer of Bloom Burton commented, "We are honoured to celebrate Canada's top healthcare leaders and welcome the public to submit award nominations for those who achieved monumental success in Canadian healthcare in the past year. We look forward to shining a well-deserved spotlight on the advancements, made by exceptional individuals, that drive our industry forward." The finalists, along with their family and friends, will be invited to attend the Bloom Burton Award Gala on September 25, 2025 at The Ritz-Carlton, Toronto. Each finalist will receive a $25,000 cash prize, and a single winner will receive the 2025 Bloom Burton Award. To submit a nomination, please send a one-page letter by March 31, 2025 to:Karen LiManager, Marketing and Communicationskli@ For table sponsorship and other inquiries:Brian BloomChairman & CEObbloom@ About Bloom Burton & Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, strategic advisory, as well as company creation and incubation services. Bloom Burton Securities Inc. is a member of the Canadian Investment Regulatory Organization (CIRO) and is also a member of the Canadian Investor Protection Fund (CIPF). To view the source version of this press release, please visit Sign in to access your portfolio
